Skip to main navigation Skip to search Skip to main content

De novo design of self-assembling foldamers that inhibit heparin-protein interactions

  • Geronda L. Montalvo
  • , Yao Zhang
  • , Trevor M. Young
  • , Michael J. Costanzo
  • , Katie B. Freeman
  • , Jun Wang
  • , Dylan J. Clements
  • , Emma Magavern
  • , Robert W. Kavash
  • , Richard W. Scott
  • , Dahui Liu
  • , William F. Degrado

Research output: Contribution to journalArticlepeer-review

Abstract

A series of self-associating foldamers have been designed as heparin reversal agents, as antidotes to prevent bleeding due to this potent antithrombotic agent. The foldamers have a repeating sequence of Lys-Sal, in which Sal is 5-amino-2-methoxy-benzoic acid. These foldamers are designed to self-associate along one face of an extended chain in a -sheet-like interaction. The methoxy groups were included to form intramolecular hydrogen bonds that preclude the formation of very large amyloid-like aggregates, while the positively charged Lys side chains were introduced to interact electrostatically with the highly anionic heparin polymer. The prototype compound (Lys-Sal) 4 carboxamide weakly associates in aqueous solution at physiological salt concentration in a monomer-dimer-hexamer equilibrium. The association is greatly enhanced at either high ionic strength or in the presence of a heparin derivative, which is bound tightly. Variants of this foldamer are active in an antithrombin III-factor Xa assay, showing their potential as heparin reversal agents.

Original languageEnglish (US)
Pages (from-to)967-975
Number of pages9
JournalACS Chemical Biology
Volume9
Issue number4
DOIs
StatePublished - Apr 18 2014
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Fingerprint

Dive into the research topics of 'De novo design of self-assembling foldamers that inhibit heparin-protein interactions'. Together they form a unique fingerprint.

Cite this